Myeloblastic Leukemia Review Articles | Open Access Journals

Journal of Cancer Clinical Trials

ISSN: 2577-0535

Open Access

Myeloblastic Leukemia Review Articles

Acute myeloid leukaemia (AML) can be divided into two subtypes: de novo, when it is not caused by chemotherapy or another preceding haematological condition, and secondary, when it is derived from such a condition. AML is a group of neoplastic disorders characterized by an increase in the number of immature myeloid cells in the bone marrow with or without involvement of the peripheral blood. As a consequence, a bone marrow failure syndrome, producing anaemia, granulocytopenia and thrombocytopenia, with its clinical manifestations characterized by dyspnoea and weakness, infections and bleeding, is seen. If untreated, AML is usually fatal within weeks from the time of diagnosis. AML is more frequently seen in older adults. The incidence in the US is 3.5 cases per 100 000, being higher in patients over the age of 65 years compared with younger patients (15.9 vs 1.7, respectively), and causes approximately 2.1% of all cancer deaths in the US, with an annual death rate of 3.2 per 100 000 in 2007.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Clinical Sciences

Google Scholar citation report
Citations: 90

Journal of Cancer Clinical Trials received 90 citations as per Google Scholar report

Journal of Cancer Clinical Trials peer review process verified at publons

Indexed In

arrow_upward arrow_upward